Hans-Aloys Wischmann

Hans-Aloys Wischmann

Auto-generated profile, based on publicly available information

Hans-Aloys Wischmann

Institute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
RSRicarda Sophia Schulz
Ricarda Sophia Schulz
Pauline Sarah MünchenbergPauline Sarah Münchenberg
Pauline Sarah Münchenberg
CTCarmen Thomas
Carmen Thomas
ADAlice Charlotte Dorison
Alice Charlotte Dorison
HWHans-Aloys Wischmann
Hans-Aloys Wischmann
JSJannis Seemann
Jannis Seemann
Background: Epilepsy and other seizure disorders are medical conditions that impose a substantial health economic burden on society given their considerable costs of illness and use of healthcare resources. The ALVEEG trial aims to tackle resource shortages in clinical settings and optimize patient management by evaluating outpatient ambulatory long-term video electroencephalograms (ALVEEGs) as a new diagnostic pathway to diagnose and manage epilepsy and other seizure disorders. The health economic evaluation alongside this trial aims to determine the cost-effectiveness and cost-utility of ALVEEGs for affected patients presenting themselves at participating epilepsy centers in Germany. Methods: This study protocol comprises the rationale and methods of the health economic evaluation of ALVEEGs embedded into the ALVEEG project. We will perform cost-effectiveness and cost-utility analyses, with the outcomes being a priori defined endpoint measures of the main trial. We will consider the proportion of solved clinical queries (primary endpoint), the number of hospital stays, the in-patient length of stay, and quality-adjusted life years for the here presented health economic evaluation. Costs will be collected by the participating health insurance companies alongside the trial, with the evaluation being conducted from a statutory health insurance perspective within the German healthcare system. The reporting of the economic evaluation follows the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Discussion: The health economic evaluation of ALVEEGs for patients affected by epilepsy and other seizure disorders within the German healthcare system will deliver insightful evidence on the cost-effectiveness and cost-utility of the intervention and hence guide policy and decision makers regarding a potential inclusion of ALVEEGs into the health benefit basket of the statutory health insurance scheme. Trial registration: German Clinical Trials Register (DRKS00032220), date registered: December 11, 2023.

16 March 2026 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
MKMascha Kern
Mascha Kern
HWHans-Aloys Wischmann
Hans-Aloys Wischmann
AMAlex Müller
Alex Müller
TKTobias Kurth
Tobias Kurth
STStefanie Theuring
Stefanie Theuring
Background: Sex and gender both affect health outcomes, often in complex ways that intertwine biological and social influences. While researchers have criticized the conflation of sex and gender in quantitative studies, it remains a challenge to analytically disentangle them. We investigated an approach to conceptualize sex and gender as interrelated constructs embedded within a specific social context and estimate their direct effects on health outcomes simultaneously. Methods: To analyze migraine and stroke incidence from 2011 until 2022, we used longitudinal data from the representative German Socio-Economic Panel (SOEP) within a causal framework. We applied a directed acyclic graph (DAG) to formalize hypothesized effects of sex and gender. Gender was modeled as an unobserved latent variable, influenced by sex assigned at birth and indicated by a set of gender-related variables. We codified the causal model as a structural equation model (SEM), enabling the joint estimation of the latent gender construct and the direct effects of both sex and gender on the health outcomes. We tested prior hypotheses in the SEM and explored additional relationships using causal discovery techniques. Results: Migraine incidence was 3.1 times higher among participants of female sex (6.2% vs. 2.0%). Sex had the strongest effect on reporting a new migraine diagnosis ( β = 0.044, 95% CI [0.033, 0.056], p < .001), while gender showed no direct effect. Stroke incidence was lower among female respondents (1.2% vs. 1.7%), with sex showing a statistically significant negative effect, indicating that slightly fewer female persons reported a new stroke diagnosis ( β = -0.010, 95% CI [-0.017, -0.004], p < .01). In contrast, gender showed a small, but significant positive effect ( β = 0.006, 95% CI [0.002, 0.009], p < .01), suggesting that gender-related characteristics that were more frequently reported by female individuals had an effect on stroke incidence. Conclusions: Both sex and gender differentially affected stroke, whereas only sex showed a direct effect on migraine. We demonstrated that biological and social dimensions of sex and gender can be systematically addressed within the same model including gender as an unobserved latent variable, while remaining attentive to contextual complexity.

27 March 2026 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
LKLaura Klaming
Laura Klaming
HWHans-Aloys Wischmann
Hans-Aloys Wischmann
MGMurray Gillies
Murray Gillies
ZNZiad Nasreddine
Ziad Nasreddine
The growing prevalence of dementia highlights the need for a risk assessment tool that is accessible, facilitates the identification of at-risk individuals, and provides evidence-based guidance on how to reduce dementia risk. We developed, deployed, and evaluated the MoCA-CHAI, a self-administered, online dementia risk assessment for the general public. We provide a brief overview of its development, the self-enrolled population that has completed it, and a preliminary evaluation of its predictive performance. Drawing on the 2024 Lancet report, we developed the MoCA-CHAI translating the 14 identified risk factors into a questionnaire. We used the MoCA XpressO as a measure of cognitive impairment and a proxy measure for the probability of having or developing dementia. The MoCA-CHAI was completed by 3886 people. Based on their XpressO score, 11.3% showed a high probability of cognitive impairment. Using a logistic regression analysis, we found that each 1-point increase in MoCA-CHAI score decreases the odds of having cognitive impairment by 1%. Physical inactivity and exposure to air pollution are the most prevalent risk factors across the lifespan. Depression is more prevalent in young adults, while high cholesterol, hypertension, diabetes, and excessive alcohol consumption are more prevalent in middle-aged and older adults. These findings demonstrate that the MoCA-CHAI provides insight into modifiable lifestyle factors and dementia risk. Differences in prevalences of risk factors indicate that prevention strategies need to be tailored to age-specific risk profiles. The MoCA-CHAI may help identify at-risk individuals who could benefit from targeted prevention and monitoring.

18 August 2026 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
HWHans-Aloys Wischmann
Hans-Aloys Wischmann
WHWillem Huijbers
Willem Huijbers
MGMurray Gillies
Murray Gillies
ZNZiad Nasreddine
Ziad Nasreddine
Background: With growing prevalence of mild cognitive impairment and dementia, online self-administered pre-screening tests hold the promise to more objectively identify individuals who stand to benefit from prioritized access to supervised cognitive testing and in-depth neurological evaluation, while reducing the burden of unnecessary tests for physicians and the health care system. Objective: We aimed to quantify practice effects in same-day and mid-term test-retest applications of the XpressO cognitive pre-screening test, to develop novel methods to stratify practice effects in the absence of ground truth, to quantify the discrimination power in retests, and to incorporate information from practice effects to improve the discrimination power for retests. Methodology: We performed a retrospective observational study to analyse data from a large, self-enrolled online cohort. We created descriptive statistics for test-retest comparisons of all relevant performance metrics, developed an unsupervised machine learning approach to impute the cognitive status of participants, and used this to compare the discrimination power in the initial test-retests on the same day or after a gap of two weeks or more. Results: Significant practice effects were found in a self-enrolled online population, in same-day retests and after several weeks, with differentially larger effects observed for presumably cognitively impaired participants. Practice effects reduced the discrimination power of the original test score in the retests. Conclusion: Whenever participants can perform unlimited, uncontrolled, and unsupervised practice sessions, increased task variation is desirable for future cognitive pre-screening tests. Quantified practice effects contain independent, additional predictive information regarding the cognitive status of online participants.